← Back

Sichuan Biokin Pharmaceutical Co. Ltd. A

Sichuan Biokin Pharmaceutical Co., Ltd. is a China-based company engaged in the research, development, manufacture, and sale of biomedicines, with activities in antibody drug conjugates, guidance navigation and control, and antibody radionuclide conjugates in China and internationally. Its product offerings include anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines. The company was founded in 1996 and is headquartered in Chengdu, China.

Price · split & dividend adjusted
News & notes moving 688506.CG
688506.CG▲2

Over 20 Shanghai-Listed Companies Release Positive Announcements on Buybacks, Earnings, and Interim Dividends

This evening, more than 20 companies listed on the Shanghai Stock Exchange released a wave of positive signals, covering share buybacks and stake increases, strong operating results, and interim dividend returns. Four companies announced new buyback plans, with a combined proposed buyback cap of 320 million yuan. Three companies announced new stake increase plans, with a combined proposed increase cap of 166 million yuan. Another six companies disclosed progress updates on buybacks. On the operational front, Pingdingshan Tianan Coal Mining reported a 25.58 percent year-on-year rise in commercial coal sales revenue in the first half. Sichuan Biokin Pharmaceutical received clinical trial approval for its injectable drug BL-B01D1 for subcutaneous administration. Farsoon Technologies posted an 87 percent year-on-year increase in net profit attributable to the parent company in the first half. Jiangsu Beiren Robot System projected a net profit attributable to the parent company of 15.8213 million yuan for the first half of 2026, swinging to a profit. Acter Group reported a 205 percent year-on-year jump in net profit for the first half. In terms of shareholder returns, Eastroc Beverage plans to distribute approximately 2.2 billion yuan in cash dividends for the half year. OPT Machine Vision Tech disclosed that its actual controller has proposed an interim dividend arrangement. And the controlling shareholder of Lead Intelligent Equipment voluntarily committed not to reduce its stake in the company within the next 12 months.
601666.CG · Demand · Positive Reported 25.58% YoY rise in commercial coal sales revenue in H1
605499.CG · Capital · Positive Plans to distribute ~2.2 billion yuan in cash dividends for H1
688218.CG · Capital · Positive Projected net profit of 15.8213 million yuan for H1 2026, swinging to profit
688433.CG · Capital · Positive Posted 87% YoY increase in net profit attributable to parent in H1
688506.CG · Technology · Positive Received clinical trial approval for injectable drug BL-B01D1 for subcutaneous administration
688686.CG · Capital · Positive Actual controller proposed interim dividend arrangement, a positive capital return signal.
Read original ↗